Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 21, 2019
Pharmacy Choice - News - Generic Drugs - March 21, 2019

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/14/19 - Biocon biosimilar plant criticized again by the FDA [Sport360]
The plant in India where Biocon makes the biosimilars it shares with Mylan was given a clean bill of health by the FDA last yearbut not for long. The most recent citation of the Bangalore plant includes only two observations, unlike in 2017 when a long list of problems led the FDA to delay approvals of the biosimilars that Mylan and Biocon were dev
3/14/19 - Endo International plc Announces Proposed Private Offering Of Senior Secured Notes
Endo International plc today announced that Par Pharmaceutical, Inc., its wholly-owned subsidiary, intends to offer senior secured notes, subject to market and customary conditions. Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence i
3/14/19 - FDA approves a new generic valsartan [Sudan Tribune]
Today, the U.S. Food and Drug Administration approved a new generic of Diovan. The FDA prioritized the review of this drug application to help relieve the recent shortage of this critical medicine as a result of multiple recalls of generic valsartan products from several manufacturers due to the finding that certain lots of valsartan and other ARB
3/14/19 - Fourth Trastuzumab Biosimilar Granted FDA Approval [T-break Tech (Middle East)]
Officials with the FDA have approved trastuzumab-qyyp, a biosimilar to trastuzumab, according to a press release.1. Approximately 15% to 30% of breast cancers and 10% to 30% of gastric cancers are HER2-positive which is associated with aggressive disease and poor prognoses for patients, Dr Mark Pegram, associate director for clinical research at th
3/14/19 - New generic valsartan approved to address shortages
The FDA has prioritised the review of this drug application after multiple recalls of generic valsartan products from several manufacturers... The post New generic valsartan approved to address shortages appeared first on European Pharmaceutical Review.
3/14/19 - Rep. Kelly Introduces Legislation to Expand Access to Lower Cost Generic Drugs
Robin Kelly, D- Illinois, issued the following news release:. Congresswoman Robin Kelly, chair of the Congressional Black Caucus Health Braintrust and member of the Health subcommittee on Energy and Commerce, has introduced the Orange Book Transparency Act to increase access to lower cost generic drugs and bolster competition within the generic dru
3/14/19 - Rep. Kuster Raises Concern About Practices of Pharmaceutical Companies to Suppress Generic Drugs, Increase Prescription Drug Prices
Ann Kuster, D- New Hampshire, issued the following news release:. Some pharmaceutical companies use U.S. Food and Drug Administration safety rules as a tool to illegitimately slow the approval or development of generic prescription drugs. We should be doing everything we can to lower costs for people in New Hampshire and across the country and that
3/14/19 - Sagent acquires US facility with an eye on future biosimilar products [Tehran Times (Iran)]
Sagent purchases Xellias FDA- approved site in North Carolina, which has capabilities to manufacture both small molecule and biologic products. Sagent Pharmaceuticals, part of the Nichi-Iko company, invested in a manufacturing site in North Carolina, US. The Raleigh- based site can manufacture both small molecule and biologic products, and is US Fo
3/13/19 - "Lowering the Cost of Prescription Drugs: Reducing Barriers to Market Competition."
*Welcome to the first hearing of the Health Subcommittee on drug pricing. *The United States has the lowest generic drug prices in the world, so where there's competition between brand drugs and multiple generics, it works. *We're examining the CREATES Act authored by Representatives Cicilline, Sensenbrenner, Nadler, Collins, Welch and McKinley, an
3/13/19 - Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA
The study is expected to enroll 400 participants at approximately 30 sites in Europe. Abbvie's HUMIRA recorded sales of about US $20 billion in 2018, making it the largest-selling blockbuster medicine worldwide. Robert Wessman, founder and chairman of the board, said: "We are delighted that, after intensive preparation, our first biosimilar prod
3/13/19 - Amneal Announces Launch of Rivastigmine Transdermal System
BRIDGEWATER- Amneal Pharmaceuticals, Inc., today announced that it has launched its generic version of Exelon Patch, 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is an integrated pharmaceutical company focused on developing, manufacturing and distributing generic, brand and
3/13/19 - Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) gets downgraded to Hold by Needham & Company LLC
Analyst Ratings For Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Today, Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) stock was downgraded by Needham & Company LLC from Buy to Hold. There are 3 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) i
3/13/19 - Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) gets downgraded to Hold by Needham & Company LLC with a price target of $22.20
Analyst Ratings For Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Today, Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) stock was downgraded by Needham & Company LLC from Buy to Hold with a price target of $22.20. There are 3 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Amphastar Pharm
3/13/19 - An Investor's Overview to Biosimilars
Also called the Biosimilars Act, it was signed into law by former President Barack Obama in March 2010 with the purpose of paving the way for regulatory approvals for generic biologics which are also called biosimilars that are similar to the generic drug pathway found under the Hatch-Waxman Act. According to the US Food and Drug Admini
3/13/19 - FDA approves a new generic valsartan
Today, the U.S. Food and Drug Administration approved a new generic of Diovan. The FDA prioritized the review of this drug application to help relieve the recent shortage of this critical medicine as a result of multiple recalls of generic valsartan products from several manufacturers due to the finding that certain lots of valsartan and other ARB
3/13/19 - Generic Drugs Market Analysis & Forecast 2019: Teva, Novartis - Sandoz, Mylan, Sun Pharmaceut
Los Angeles, CA 03/13/2019 The report presented here is a comprehensive research study that explores key aspects of the global Generic Drugs market, including market dynamics, segmentation, competition, and regional growth. Each section of the report reveals critical information about the global Generic Drugs market that could be used to ensu
3/13/19 - Kuster Raises Concern about Practices of Pharmaceutical Companies to Suppress Generic Drugs, Increase Prescription Drug Prices
-Today, Congresswoman Annie Kuster, a member of the House Energy and Commerce Subcommittee on Health, expressed her concern about the practice of some pharmaceutical companies inhibiting the rollout of generic versions of prescription drugs. Some pharmaceutical companies use U.S. Food and Drug Administration safety rules as a tool to illegitimately
3/13/19 - Pharmaceutical Contract Manufacturing Market Grow at a CAGR at 7.2% Till 2023 | By Size, Share, Industry Growth, Profits and Regional Analysis
The Report on the Global Pharmaceutical Contract Manufacturing Market Covers Historical Market Trends, Current Market Dynamics, Market Valuation by Segmentation as well as Region, Country-Level Analysis for Every Segment, Key Player's Market Share Analysis, Competitive Landscape and Supply Chain Analysis. Pharmaceutical Contract Manufacturing...
3/13/19 - Piramal Announces the Launch of Cinacalcet by its partner, Slate Run Pharmaceuticals, in the U.S.
MUMBAI- Piramal Enterprises Limited announced that one of its partners for its global pharma businesses Slate Run Pharmaceuticals LLC., has launched generic cinacalcet hydrochloride tablets in the United States. Piramal's subsidiary, Piramal Healthcare Limited, has partnered with Slate Run Pharmaceuticals with the goal of developing a non-infringin
3/13/19 - Rep .Kuster, Ann - (D-NH) News Release
-Today, Congresswoman Annie Kuster, a member of the House Energy and Commerce Subcommittee on Health, expressed her concern about the practice of some pharmaceutical companies inhibiting the rollout of generic versions of prescription drugs. Some pharmaceutical companies use U.S. Food and Drug Administration safety rules as a tool to illegitimately
3/13/19 - Rep. Robin Kelly (D-IL) News Release
Congresswoman Robin Kelly, chair of the Congressional Black Caucus Health Braintrust and member of the Health subcommittee on Energy and Commerce, has introduced the Orange Book Transparency Act to increase access to lower cost generic drugs and bolster competition within the generic drug marketplace to help reduce drug costs. The Orange Book is an
3/12/19 - Agency Information Collection Activities; Proposed Collection; Comment Request; Review Transparency and Communication in Reviews of 351(k) Biologics License Applications in Biosimilars User Fee Act
Agency: " Food and Drug Administration, HHS." Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the no
3/12/19 - Amneal Announces Launch of Rivastigmine Transdermal System
According to IQVIA?, U.S market annual sales for the 12 months ended January 2019 for Rivastigmine Transdermal System is estimated to be approximately $214 million. About Amneal Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is an integrated pharmaceutical company focused on developing, manufacturing and distributing generic, bra
3/12/19 - ANTARES PHARMA, INC. - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion in conjunction with Item 1 A. and our audited consolidated financial statements included elsewhere in this annual report. Some of the statements in the following discussion are forward-looking statements. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and...
3/12/19 - Elite Pharmaceuticals Enters into Strategic Marketing Alliance with Lannett for Generic Adderall
NORTHVALE- Elite Pharmaceuticals, Inc. announced today that it has entered into a license, supply, and distribution agreement with Lannett Company, Inc.. According to IQVIA data, the Adderall and its equivalents had total U.S. sales of $361 million for the twelve months ending January 2019. Lannett Company, founded in 1942, develops, manufactures,
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415